肯尼亚西部妊娠与非妊娠女性无并发症恶性疟中卢美凡群药代动力学研究
妊娠状态或孕龄显著影响卢美凡群的清除率和中央分布容积,妊娠女性药物暴露低于非妊娠女性,但28天PCR校正治愈率两组均为100%。
要点
- 妊娠状态或孕龄显著影响卢美凡群清除率和中央分布容积。
- 妊娠女性卢美凡群暴露低于非妊娠女性,AUC、Cmax和Day 7浓度GMR均低于1。
- 两组28天PCR校正治愈率均为100%,但妊娠女性暴露降低可能增加治疗失败风险。
核心结论
- 妊娠女性无并发症恶性疟感染时卢美凡群暴露低于非妊娠女性,可能增加蒿甲醚-卢美凡群治疗失败风险,尤其在药物敏感性降低时。
- 建议持续评估和监测蒿甲醚-卢美凡群在妊娠女性中的疗效。
研究设计与样本
- 参与者接受标准剂量蒿甲醚-卢美凡群(80/480 mg)每日两次共3天,采集密集静脉血浆样本。
- 采用非线性混合效应模型表征卢美凡群药代动力学,并通过全协变量建模方法评估妊娠对所有药代动力学参数的影响。
主要发现
- 卢美凡群浓度-时间数据由二室处置模型充分描述,含灵活转运吸收和一级消除。
- 妊娠状态或孕龄对卢美凡群清除率和中央分布容积有显著影响,估计妊娠对CL和Vc的影响分别为23%(95%CI: 10.8-34.8%)和28%(95%CI: 7.3-51.8%)。
- 妊娠女性药物暴露低于非妊娠女性,AUC、Cmax和Day 7浓度的几何均值比分别为0.76(95%CI: 0.57-1.01)、0.79(95%CI: 0.63-0.99)和0.69(95%CI: 0.51-0.94)。
- 其他协变量未显著影响卢美凡群药代动力学。
- 妊娠和非妊娠女性28天PCR校正寄生虫学治愈率均为100%。
临床怎么用
- 临床应关注妊娠女性使用蒿甲醚-卢美凡群时卢美凡群暴露降低的现象,尤其当怀疑药物敏感性降低时。
- 建议对妊娠女性进行蒿甲醚-卢美凡群疗效的持续评估和监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This study intends to assess the pharmacokinetic properties and treatment response of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria infection in Western Kenya. METHODS: Seventy-five women with uncomplicated P. falciparum malaria were enrolled, including 25 non-pregnant, 30 pregnant women in the second trimester and 20 pregnant women in their third trimester. The participants received a standard dose of artemether-lumefantrine (80/480 mg) twice daily for 3 days. Densely venous plasma samples were collected. Nonlinear mixed-effects modelling was used to characterize the pharmacokinetic properties of lumefantrine, and the effects of pregnancy was assessed on all pharmacokinetic parameters by a full covariate modelling approach. RESULTS: The concentration-time data of lumefantrine were described adequately by a two-compartment disposition model, with a flexible transit absorption and first-order elimination. Covariate modelling results demonstrated that pregnancy status or gestational age had a significant impact on both elimination clearance (CL) and the central volume of distribution (Vc) of lumefantrine. The estimated pregnancy effects on CL and Vc were 23% (95%CI: 10.8-34.8%) and 28% (95%CI: 7.3-51.8%), respectively. Pregnant women exhibited lower drug exposure compared to non-pregnant women, with the geometric mean ratios (GMRs) of 0.76 (95% CI: 0.57-1.01), 0.79 (95% CI: 0.63-0.99) and 0.69 (95% CI: 0.51-0.94) for area under the concentration-time curve (AUC), maxinum concentration (Cmax) and Day 7 concentration, respectively. Other covariates did not significantly affect the pharmacokinetics of lumefantrine. The 28-day polymerase chain reaction (PCR)-corrected parasitological cure was 100% for both pregnant and non-pregnant women. CONCLUSIONS: The exposure to lumefantrine was lower in pregnant women, compared to non-pregnant women, with uncomplicated P. falciparum infection. This lower drug exposure might increase the risk of treatment failure with artemether-lumefantrine in pregnant women, especially if susceptibility to either drug is reduced. Continuous assessment and monitoring of the efficacy of artemether-lumefantrine in pregnant women are warranted.
引用
- Juma E, Ding J, Ongas M, et al. Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Western Kenya. Br J Clin Pharmacol. 2025. PMID: 41152149. doi:10.1111/bcp.70318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。